UNCY UNICYCIVE THERAPEUTICS INC

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Unicycive Therapeutics to Participate in a Fireside Chat at the Virtual Lytham Partners Fall 2024 Investor Conference on October 1, 2024

LOS ALTOS, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will participate in a fireside chat at the virtual Lytham Partners Fall 2024 Investor Conference on Tuesday, October 1, 2024 at 11:00 a.m. ET.

A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section:. An archive of the webcast will be available for three months.

About Unicycive Therapeutics

Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases. Unicycive’s lead drug candidate, oxylanthanum carbonate (OLC), is a novel investigational phosphate binding agent being developed for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis. UNI-494 is a patent-protected new chemical entity in clinical development for the treatment of conditions related to acute kidney injury. For more information, please visit and follow us on , , and .

Investor Contact:



(650) 543-5470

SOURCE: Unicycive Therapeutics, Inc.



EN
24/09/2024

Underlying

UNCYUNICYCIVE THERAPEUTICS INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on UNICYCIVE THERAPEUTICS INC

 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results...

Unicycive Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update - Type A Meeting requested with U.S. Food and Drug Administration (FDA) for resolution of the Complete Response Letter (CRL) for oxylanthanum carbonate (OLC) - OLC pivotal study data, published in the Clinical Journal of the American Society of Nephrology (CJASN), demonstrated OLC was well tolerated and enabled serum phosphate control in over 90% of patients with a low pill burden - Ended Q2 with $22.3 million of cash with expected runway into the second half of 2026 LOS ALTOS, Calif...

August 14, 2025 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbo...

Unicycive Therapeutics Announces the Publication of Oxylanthanum Carbonate Pivotal Trial Data in Clinical Journal of the American Society of Nephrology OLC was well-tolerated and enabled serum phosphate control in over 90% of patients with a low pill burden LOS ALTOS, Calif., July 24, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company” or “Unicycive”), today announced the publication of pivotal trial data describing the safety and tolerability of oxylanthanum car...

July 24, 2025 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Pric...

Unicycive Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement --Nasdaq compliance follows reverse stock split previously announced on June 17, 2025 LOS ALTOS, Calif., July 08, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced it has regained compliance with the Nasdaq Stock Market (“Nasdaq”) continued listing standard for minimum share price under Rule 5550(a)(2) of the Nasdaq Listing Qualifications. This u...

July 8, 2025 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Ki...

Unicycive Therapeutics to Present at the H.C. Wainwright 4th Annual Kidney Virtual Conference LOS ALTOS, Calif., July 07, 2025 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease, today announced that Shalabh Gupta, M.D., Chief Executive Officer, will participate in a fireside chat at the H.C. Wainwright 4th Annual Kidney Virtual Conference on Monday, July 14, 2025 at 11 a.m. ET. A link to the webcast may be accessed on the Unicycive website under the I...

July 7, 2025 1 EN
 PRESS RELEASE
Free
UNCY UNICYCIVE THERA...

Unicycive Therapeutics Announces Receipt of Complete Response Letter f...

Unicycive Therapeutics Announces Receipt of Complete Response Letter for Oxylanthanum Carbonate for the Treatment of Hyperphosphatemia in Patients with Chronic Kidney Disease on Dialysis --Complete Response Letter (CRL) cited deficiencies previously identified at a third-party manufacturing vendor unrelated to Oxylanthanum Carbonate (OLC) --No other concerns stated, including pre-clinical, clinical, or safety data --The Company identified a second manufacturing vendor that has already produced OLC drug product, which could also be used to support the resolution of the Clinical Ma...

June 30, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch